- Home
- LIVN vs XENE Comparison
LIVN vs XENE Comparison
Compare LIVN & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LIVN | XENE |
|---|---|---|
| Founded | 1987 | 1996 |
| Country | United Kingdom | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.2B |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LIVN | XENE |
|---|---|---|
| Price | $64.50 | $56.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $72.43 | $67.17 |
| AVG Volume (30 Days) | 647.2K | ★ 933.9K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $311,000.00 |
| Revenue This Year | $9.79 | N/A |
| Revenue Next Year | $6.63 | $2,496.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $35.00 | $28.19 |
| 52 Week High | $71.58 | $62.91 |
Technical Indicators
Market Signals| Indicator | LIVN | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 50.80 | 51.84 |
| Support Level | $61.63 | $52.55 |
| Resistance Level | $65.61 | $56.66 |
| Average True Range (ATR) | 1.99 | 1.79 |
| MACD | 0.27 | -0.47 |
| Stochastic Oscillator | 42.81 | 17.41 |
Price Performance
Historical ComparisonAbout LIVN LivaNova PLC
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.